Skip to content

Study · Case report or series · n = 1 · 2023

2 results

A beneficial role of GLP-1 receptor agonist therapy in ABCC8-MODY (MODY 12).

Nakhleh A, Goldenberg-Furmanov M, Goldstein R, Shohat M, Shehadeh N

Journal of diabetes and its complications28 Jul 2023Cited by 8 (Europe PMC)

PMID37536118 (opens in a new tab)DOI10.1016/j.jdiacomp.2023.108566 (opens in a new tab)PepBankPUB-37536118
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a 49-year-old woman with ABCC8-MODY previously on insulin, glycemic control improved significantly after transition to semaglutide.

    In plain wordsIn one woman with a rare inherited form of diabetes, blood sugar control improved after she switched from insulin to semaglutide.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedGlycemic control after switch from insulin
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    experienced significant improvements in glycemic control and weight loss after transitioning to semaglutide.
    1 context sentence
    Summary · context
    This report presents a successful treatment of a 49-year-old woman diagnosed with ABCC8-MODY using the GLP-1 RA semaglutide.
  2. 02HumanCase report or seriesEfficacy outcome

    In a 49-year-old woman with ABCC8-MODY previously on insulin, weight loss occurred after transition to semaglutide.

    In plain wordsIn one woman with a rare inherited form of diabetes, she lost weight after switching from insulin to semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss after switch from insulin
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    experienced significant improvements in glycemic control and weight loss after transitioning to semaglutide.
    1 context sentence
    Summary · context
    This report presents a successful treatment of a 49-year-old woman diagnosed with ABCC8-MODY using the GLP-1 RA semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.